Mutations such as TP53 (30.0%), TET2 (40.0%), RHOAG17V (30.0%), DNMT3A (20.0%), and EZH2 (10.0%) were frequent among the 10 PTCL-NOS patients. This evidence concerns the gene EZH2 and mature T-cell and NK-cell non-Hodgkin lymphoma.